Global /Austria /Healthcare /Drug Manufacturers - General /MARI

Marinomed Biotech AG

MARI

• VIE: MARI • Delayed

13.10EUR -4.4%

15.22 USD

As of 5 June 2026, Marinomed Biotech AG has a market cap of $29.24M USD, ranking #34438 globally and #62 in Austria. It ranks #3106 in the Healthcare sector, and #1055 in the Drug Manufacturers - General industry.

Global Rank

34438

Country Rank

Sector Rank

3106

Industry Rank

1055

Key Stats

Market Cap

$29.24MUSD

25.21M EUR

Enterprise Value

$41.6MUSD

35.82M EUR

Revenue (TTM)

$9.23MUSD

7.96M EUR

EBITDA (TTM)

$55.77KUSD

48.02K EUR

Net Income (TTM)

$20.9MUSD

18.02M EUR

EBITDA Margin

0.6%

Profit Margin

226%

PE Ratio

1.4

Forward PE

9.2

PS Ratio

3.2

PB Ratio

-3.6

Company Profile

Country (HQ)

Austria

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Andreas Grassauer open_in_new

Employees

Founded

2006

Website

marinomed.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-4.4%	-7.1%	-7.7%	-30%	-36%	-31%	5.6%	-63%	-90%

News

Markets

Exchange	Ticker	Price	Quotes
Vienna Stock Exchange (VIE) MIC: XVIE PRIMARY	MARI ISIN: ATMARINOMED6 Shares Out.: Shares Outstanding: 2.3M¹ Shares Float: 2.283M² TV: TradingView: VIE: MARI SA: Stock Analysis: VIE: MARI YF: Yahoo Finance: MARI.VI GF: Google Finance: VIE: MARI BA: Barron's: MARI MS: Morningstar: XVIE: MARI	13.10 EUR	TV: TradingView: VIE: MARI SA: Stock Analysis: VIE: MARI YF: Yahoo Finance: MARI.VI GF: Google Finance: VIE: MARI BA: Barron's: MARI MS: Morningstar: XVIE: MARI

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Marinomed Biotech AG

Marinomed Biotech AG, a biopharmaceutical company, develops therapeutic products for indications in virology and immunology in Austria, other European countries, and internationally. It operates through Virology, Immunology, and Other segments. The company’s products pipeline includes Budesolv for the treatment of allergic rhinitis; Tacrosolv, which is in Phase II clinical trial for inflammatory eye diseases; and Inhaleen for viral infection of the upper and lower respiratory tract. It also provides Solv4U which offers formulation development and biopharmaceutical testing services. It has a technology partnership with SPH Sine Pharmaceutical Laboratories Co. Ltd. The company was formerly known as Marinomed Biotechnologie GmbH and changed its name to Marinomed Biotech AG in June 2017. Marinomed Biotech AG was incorporated in 2006 and is headquartered in Korneuburg, Austria.

Similar Companies

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 3M%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 2M%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 1M%	97.4	United States
Roche Holding AG SIX: RO	$323.4B 256.25B CHF 1M%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$289.25B 215.59B GBP 989K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$276.26B 218.9B CHF 945K%	20.5	Switzerland

chevron_leftBack